Related Experiment Video
Updated: Aug 6, 2025
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Published on: March 1, 2019
Pseudotyped Viruses for the Alphavirus Chikungunya Virus
Jiajing Wu1, Weijin Huang2, Youchun Wang3,4
1Beijing Yunling Biotechnology Co., Ltd, Beijing, China.
Abstract:
Members of the genus Alphavirus are mostly mosquito-borne pathogens that cause disease in their vertebrate hosts. Chikungunya virus (CHIKV), which is one member of the genus Alphavirus [1], has been a major health problem in endemic areas since its re-emergence in 2006. CHIKV is transmitted to mammalian hosts by the Aedes mosquito, causing persistent debilitating symptoms in many cases. At present, there is no specific treatment or vaccine. Experiments involving live CHIKV need to be performed in BSL-3 facilities, which limits vaccine and drug research. The emergence of pseudotyped virus technology offered the potential for the development of a safe and effective evaluation method. In this chapter, we review the construction and application of pseudotyped CHIKVs, the findings from which have enhanced our understanding of CHIKV. This will, in turn, enable the exploration of promising therapeutic strategies in animal models, with the ultimate aim of developing effective treatments and vaccines against CHIKV and other related viruses.
Insights
Chikungunya virus (CHIKV) research is limited by safety requirements. Pseudotyped CHIKV technology offers a safer method for developing treatments and vaccines against this debilitating mosquito-borne alphavirus.
Area of Science:
- Virology
- Infectious Diseases
- Public Health
Background:
- Alphavirus genus includes mosquito-borne pathogens like Chikungunya virus (CHIKV).
- CHIKV re-emerged in 2006, causing significant health problems due to persistent symptoms.
- Current research is hampered by the need for BSL-3 facilities for live CHIKV experiments.
Conclusions:
- Pseudotyped CHIKV is a valuable tool for advancing CHIKV research.
- Enables development of effective treatments and vaccines against CHIKV.
- Promotes exploration of therapeutic strategies for related alphaviruses.
